{
    "id": 20424,
    "fullName": "ALK E1210K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK E1210K lies within the protein kinase domain of the Alk protein (UniProt.org). E1210K has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK fusions (PMID: 29650534, PMID: 25914136, PMID: 27432227), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                },
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                },
                {
                    "id": 5054,
                    "pubMedId": 25914136,
                    "title": "ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25914136"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "E1210K",
    "createDate": "03/28/2016",
    "updateDate": "10/02/2019",
    "referenceTranscriptCoordinates": {
        "id": 102014,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220723C>T",
        "cDna": "c.3628G>A",
        "protein": "p.E1210K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5415,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5439,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5422,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5483,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5431,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alunbrig (brigatinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5490,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",
            "molecularProfile": {
                "id": 20888,
                "profileName": "NPM1 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5029,
                    "pubMedId": 25749034,
                    "title": "NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25749034"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8649,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alunbrig (brigatinib) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 20889,
                "profileName": "EML4 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 20889,
                "profileName": "EML4 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 20889,
                "profileName": "EML4 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8650,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 20889,
                "profileName": "EML4 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14557,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung carcinoma harboring EML4-ALK progressed on treatment with Xalkori (crizotinib) and was subsequently found to harbor a secondary resistance mutation, ALK E1210K (PMID: 29636358).",
            "molecularProfile": {
                "id": 20889,
                "profileName": "EML4 - ALK ALK E1210K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 26388,
                "profileName": "EML4 - ALK ALK D1203N ALK E1210K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alunbrig (brigatinib) when compared to cells expressing EML4-ALK in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 26388,
                "profileName": "EML4 - ALK ALK D1203N ALK E1210K"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 26388,
                "profileName": "EML4 - ALK ALK D1203N ALK E1210K"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8657,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K did not response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 26388,
                "profileName": "EML4 - ALK ALK D1203N ALK E1210K"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 26388,
                "profileName": "EML4 - ALK ALK D1203N ALK E1210K"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14089,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ALK G1269A was identified as an acquired mutation in an ALK-positive non-small cell lung cancer patient harboring ALK E1210K and D1203N, who developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).",
            "molecularProfile": {
                "id": 29945,
                "profileName": "ALK rearrange ALK E1210K ALK D1203N ALK G1269A"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14558,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK and ALK E1210K eventually progressed on treatment with Alunbrig (brigatinib) and was subsequently found to have acquired another resistance mutation, ALK S1206C in cis (PMID: 29636358).",
            "molecularProfile": {
                "id": 30243,
                "profileName": "EML4 - ALK ALK S1206C ALK E1210K"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8646,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ALK-rearranged non-small cell lung cancer demonstrated disease progression when treated with Xalkori (crizotinib) due to a secondary acquired resistance mutation, ALK E1210K (PMID: 27432227).",
            "molecularProfile": {
                "id": 31719,
                "profileName": "ALK rearrange ALK E1210K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20886,
            "profileName": "ALK E1210K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20888,
            "profileName": "NPM1 - ALK ALK E1210K",
            "profileTreatmentApproaches": [
                {
                    "id": 16839,
                    "name": "Crizotinib",
                    "profileName": "NPM1 - ALK ALK E1210K"
                }
            ]
        },
        {
            "id": 20889,
            "profileName": "EML4 - ALK ALK E1210K",
            "profileTreatmentApproaches": [
                {
                    "id": 16778,
                    "name": "Alectinib",
                    "profileName": "EML4 - ALK ALK E1210K"
                },
                {
                    "id": 16777,
                    "name": "Ceritinib",
                    "profileName": "EML4 - ALK ALK E1210K"
                },
                {
                    "id": 16776,
                    "name": "Brigatinib",
                    "profileName": "EML4 - ALK ALK E1210K"
                },
                {
                    "id": 16779,
                    "name": "Lorlatinib",
                    "profileName": "EML4 - ALK ALK E1210K"
                }
            ]
        },
        {
            "id": 26388,
            "profileName": "EML4 - ALK ALK D1203N ALK E1210K",
            "profileTreatmentApproaches": [
                {
                    "id": 16775,
                    "name": "Lorlatinib",
                    "profileName": "EML4 - ALK ALK D1203N ALK E1210K"
                }
            ]
        },
        {
            "id": 29945,
            "profileName": "ALK rearrange ALK E1210K ALK D1203N ALK G1269A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30243,
            "profileName": "EML4 - ALK ALK S1206C ALK E1210K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31719,
            "profileName": "ALK rearrange ALK E1210K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102014,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220723C>T",
            "cDna": "c.3628G>A",
            "protein": "p.E1210K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}